ArticleCell death & disease2025
TRIM17 promotes the progression of osteosarcoma by regulating PDK1 m6A modification-mediated AKT/mTOR pathway activation through ubiquitination of FTO.
Article in Cell death & disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Decoding osteosarcoma pathogenesis: the pivotal influence of mEpigenetics · 2026Review
- TRIM47 promotes cell viability, cell cycle progression, metabolic reprogramming, and inhibits apoptosis of glioma via the NF-κB signaling pathway.Translational cancer research · 2026Article
- FTO in Bone Diseases: Functions, Mechanisms and Therapeutic Potential.Biomolecules · 2026Review
- Ubiquitination and NOncology letters · 2026Review
- TRIM17 downregulation modulates CRPC progression and enzalutamide resistance by derepressing BCL2 expression via the p53-dependent and p53-independent pathways.Cell death and differentiation · 2026Article
- Reader-dependent functional duality of FTO: a context-switching node at the intersection of immune evasion and therapeutic resistance.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Osteosarcoma is an extremely aggressive malignant tumor, which is quite common among children and has a high rate of disability and mortality. Tripartite Motif Containing 17 (TRIM17) is a member of the TRIM protein family and exhibits E3 ubiquitin ligase activity. In recent years, TRIM17 has been implicated in the development of various tumors, particularly in cancer cell clonability and survival potential and drug resistance; however, its regulatory mechanism in osteosarcoma progression remains poorly understood. We found that TRIM17 was significantly upregulated in osteosarcoma tissues and cells. Survival analysis revealed that TRIM17 was associated with poor prognosis in osteosarcoma patients. The higher the expression level of TRIM17, the worse the prognosis. Its expression was an independent prognostic factor for osteosarcoma patients. The effects of TRIM17 on osteosarcoma cell clonability and survival potential, migration, and invasion were assessed through phenotypic assays. The results showed that the downregulation of TRIM17 significantly inhibited osteosarcoma cell clonability and survival potential, migration, and invasion, whereas its overexpression promoted these processes. FTO is an m6A methyltransferase and has been identified as a new target for TRIM17. Mechanistically, TRIM17 promotes the ubiquitination and degradation of FTO protein, enhances PDK1 mRNA stability via N6-methyladenosine (m6A) modification, and subsequently promotes phosphorylation-dependent activation of the AKT/mTOR signaling pathway, thereby driving osteosarcoma malignancy. In summary, our findings suggest that TRIM17 may serve as a potential prognostic marker and therapeutic target for osteosarcoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.